Review
Copyright ©The Author(s) 2024.
World J Hepatol. May 27, 2024; 16(5): 731-750
Published online May 27, 2024. doi: 10.4254/wjh.v16.i5.731
Figure 1
Figure 1 A schematic illustration showing how glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide act on multiple organs to mitigate metabolic dysfunction-associated steatotic liver disease. GLP-1: Glucagon-like peptide 1; GIP: Glucose-dependent insulinotropic polypeptide.